Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
European Institute of Science AB (EURIS) is a Swedish biotechnology company that develops, manufactures, and markets diagnostic systems for the veterinary and human healthcare markets. The company's core technology is the TurboReader, a point-of-care (POC) instrument designed for rapid and accurate quantitative determination of biomarkers using turbidimetric immunoassays. Their product line primarily focuses on inflammatory markers, including C-reactive protein (CRP) for dogs and Serum Amyloid A (SAA) for cats and horses, as well as assays for albumin in urine. Based in the Ideon Science Park in Lund, EURIS leverages its proprietary technology to provide diagnostic solutions that facilitate immediate clinical decisions in veterinary clinics and medical laboratories. The company is publicly traded on the Spotlight Stock Market and continues to expand its assay menu for the TurboReader platform.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on European Institute of Science.